Sarepta Therapeutics, Inc. (NASDAQ:SRPT) Receives $24.72 Consensus Target Price from Analysts

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) has earned a consensus rating of “Hold” from the twenty-one analysts that are currently covering the company, MarketBeat reports. Six research analysts have rated the stock with a sell rating, six have given a hold rating and nine have issued a buy rating on the company. The average 12-month price objective among brokerages that have covered the stock in the last year is $24.7222.

Several equities analysts have weighed in on SRPT shares. Weiss Ratings upgraded Sarepta Therapeutics from a “sell (d)” rating to a “sell (d+)” rating in a research note on Monday, July 20th. Wall Street Zen upgraded shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday, July 4th. Piper Sandler decreased their price objective on shares of Sarepta Therapeutics from $23.00 to $20.00 and set a “neutral” rating for the company in a research note on Thursday, July 9th. Zacks Research downgraded Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 7th. Finally, HC Wainwright reiterated a “buy” rating on shares of Sarepta Therapeutics in a report on Tuesday, July 28th.

Institutional Investors Weigh In On Sarepta Therapeutics

A number of hedge funds have recently modified their holdings of the stock. Kestra Advisory Services LLC purchased a new stake in Sarepta Therapeutics in the 4th quarter worth about $25,000. iSAM Funds UK Ltd bought a new stake in shares of Sarepta Therapeutics in the third quarter valued at approximately $25,000. Ancora Advisors LLC boosted its holdings in Sarepta Therapeutics by 200.0% in the 3rd quarter. Ancora Advisors LLC now owns 1,500 shares of the biotechnology company’s stock worth $29,000 after buying an additional 1,000 shares during the period. Allworth Financial LP grew its stake in Sarepta Therapeutics by 2,098.8% in the 3rd quarter. Allworth Financial LP now owns 1,803 shares of the biotechnology company’s stock valued at $35,000 after buying an additional 1,721 shares in the last quarter. Finally, Parallel Advisors LLC raised its holdings in Sarepta Therapeutics by 165.3% during the 3rd quarter. Parallel Advisors LLC now owns 2,016 shares of the biotechnology company’s stock valued at $39,000 after acquiring an additional 1,256 shares during the period. Institutional investors own 86.68% of the company’s stock.

Sarepta Therapeutics News Roundup

Here are the key news stories impacting Sarepta Therapeutics this week:

• Positive Sentiment: Earnings and revenue exceeded estimates. Sarepta reported adjusted earnings of $0.64 per share, above the consensus estimate of $0.22 and the Zacks estimate of $0.58. Revenue of approximately $401.3 million also surpassed analysts’ $366.4 million forecast, producing earnings and revenue surprises of 10.35% and 12.85%, respectively. Sarepta Therapeutics Q2 Earnings and Revenues Surpass Estimates
• Positive Sentiment: Management emphasized the company’s commercial and strategic foundation. New CEO Michael Severino said Sarepta’s therapies are benefiting patients and pointed to significant future opportunities as he begins his tenure. The company also highlighted approximately $328.7 million in quarterly results tied to its business operations. Sarepta Second Quarter 2026 Financial Results
• Neutral Sentiment: The earnings call and metric reviews will be important for forward guidance. Investors are focused on management’s outlook, product performance, cash position and recent corporate developments to determine whether the quarterly beat is sustainable. Sarepta Q2 2026 Earnings Call Transcript
• Negative Sentiment: Year-over-year results deteriorated materially. Revenue fell 34.3% from the prior-year quarter, while earnings declined from $2.02 per share to $0.64. Sarepta’s net margin remained negative at 2.94%, indicating that the quarterly earnings beat does not yet represent a return to consistently strong profitability. Sarepta Q2 Earnings Report

Sarepta Therapeutics Stock Performance

Shares of SRPT opened at $15.93 on Thursday. The company has a debt-to-equity ratio of 0.56, a quick ratio of 2.62 and a current ratio of 4.63. The stock has a 50 day moving average price of $16.95 and a two-hundred day moving average price of $18.55. The firm has a market capitalization of $1.68 billion, a P/E ratio of -16.59, a P/E/G ratio of 0.18 and a beta of 0.23. Sarepta Therapeutics has a 52 week low of $14.68 and a 52 week high of $25.32.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 earnings per share for the quarter, beating analysts’ consensus estimates of $0.22 by $0.42. The company had revenue of $401.25 million for the quarter, compared to analyst estimates of $366.39 million. Sarepta Therapeutics had a positive return on equity of 7.56% and a negative net margin of 2.94%.The company’s revenue for the quarter was down 34.3% on a year-over-year basis. During the same quarter last year, the company earned $2.02 earnings per share. Equities analysts forecast that Sarepta Therapeutics will post 3.89 earnings per share for the current fiscal year.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc is a biopharmaceutical company focused on the discovery and development of precision genetic medicines for rare neuromuscular diseases. Headquartered in Cambridge, Massachusetts, Sarepta’s core expertise lies in designing RNA-targeted therapies and gene therapies that address underlying genetic mutations. The company’s mission is to transform the treatment paradigm for patients with Duchenne muscular dystrophy (DMD) and related disorders through innovative modalities.

Sarepta’s commercial products include several exon-skipping therapies approved by the U.S.